The farnesoid X receptor (FXR) is a nuclear receptor superfamily member and ligand-activated transcription factor. By binding to DNA as a monomer or a heterodimer with the common NR partner, retinoid x receptor (RXR), to FXR response elements, FXR controls the expression of numerous genes. The FXR and FXR genes are the two recognized FXR genes.

FXR is primarily expressed in the liver and small intestine, where it is critical for the metabolism of bile acids, lipids, and glucose. FXR regulates bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, as well as playing a significant role in intestinal bacterial growth and liver regeneration through its specific target genes.

FXR related products

Structure Cat No. Product Name CAS No. Product Description
(E)-GW 4064 V85288 (E)-GW 4064 1089660-72-9
Alismanol M V74026 Alismanol M 2408810-59-1 Alismanol M is an agonist of farnesoid X receptor (FXR) with EC50 of 50.25 μM.
Cilofexor V18332 Cilofexor 1418274-28-8 Cilofexor, formerly known as GS-9674, is a farnesoid X receptor (FXR) agonist.
Fargesone A V74025 Fargesone A 116424-69-2 Fargesone A is a potent and specific FXR agonist.
FXR antagonist 1 V74032 FXR antagonist 1 2295804-68-9 FXR antagonist 1 (Compound F6) is an orally bioactive, selective intestinal FXR antagonist (IC50=2.1 μM).
FXR antagonist 2 V74028 FXR antagonist 2 1660153-21-8 FXR antagonist 2 (compound A-26) is a diarylamide analogue, as well as a moderate FXR antagonist.
FXR antagonist 3 V85497 FXR antagonist 3 3024652-96-5
FXRagonist 3 V78496 FXRagonist 3 FXR agonist 3 is an anti-NASH agent that acts by activating FXR.
FXRagonist 4 V79540 FXRagonist 4 FXR agonist 4 (compound 10a) is a farnesoid X receptor (FXR) agonist/activator with EC50 of 1.05 μM.
FXRagonist 5 V74031 FXRagonist 5 2414008-05-0 FXR agonist 5 (compound 1) is an FXR agonist.
Gly-β-MCA V29731 Gly-β-MCA 66225-78-3 Gly-β-MCA is a bile acid acting as an oral and potent farnesoid X receptor (FXR) inhibitor with the potential to be usedfor the treatment of metabolic disorders.
Glyco-Obeticholic acid V40096 Glyco-Obeticholic acid 863239-60-5 Glyco-Obeticholic acid is an active metabolite of Obeticholic acid formed by a phase II metabolic reaction by conjugating with amino acid glycine.
Glyco-obeticholic acid-d5 (obeticholic acid impurity 8-d5) V79622 Glyco-obeticholic acid-d5 (obeticholic acid impurity 8-d5) Glyco-Obeticholic acid-d5 is the deuterated form of Glyco-Obeticholic acid.
HEC96719 V74024 HEC96719 2181834-03-5 HEC96719 is a selective and orally bioactive tricyclic farnesoid X receptor (FXR) agonist/activator with EC50s of 1.37 and 1.55 nM via time-resolved fluorescence energy transfer (TR-FRET) and luciferase, respectively.
Hedragonic acid V74030 Hedragonic acid 466-02-4 Hedragonic acid is an oleanane-type triterpenoid that can be extracted from the stems and roots of Hedragonic acid.
Nelumol A V74027 Nelumol A 77836-86-3 Nelumol A is a farnesoid X receptor (FXR) agonist.
Obeticholic Acid (6-ECDCA; INT-747) V1844 Obeticholic Acid (6-ECDCA; INT-747) 459789-99-2 Obeticholic Acid (INT747; 6-ECDCA; 6-Ethylchenodeoxycholic acid; trade name Ocaliva), a novel derivative of cholic acid, is a potent,orally bioactive and selectiveagonist of farnesoid X receptor (FXR) with EC50 of 99 nM, and has anticholeretic and anti-inflammatory activities.
Tauro-Obeticholic acid V40095 Tauro-Obeticholic acid 863239-61-6 Tauro-Obeticholic acid is an active metabolite of Obeticholic acid(Ocaliva; 6-ECDCA;INT747; 6-Ethylchenodeoxycholic acid) formed by conjugating with taurine, or 2-aminoethanesulfonic acid.
Tauro-β-muricholic acid-d4 sodium V78711 Tauro-β-muricholic acid-d4 sodium Tauro-β-muricholic acid-d4 (sodium) is the deuterated form of Tauro-β-muricholic acid sodium.
V023-9340 V85883 V023-9340 1048304-96-6
Contact Us